Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis
- 18 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in International Journal of Colorectal Disease
- Vol. 36 (8), 1-24
- https://doi.org/10.1007/s00384-021-03874-1
Abstract
Introduction For the past two decades, microsatellite instability (MSI) has been reported as a robust clinical biomarker associated with survival advantage attributed to its immunogenicity. However, MSI is also associated with high-risk adverse pathological features (poorly differentiated, mucinous, signet cell, higher grade) and exhibits a double-edged sword phenomenon. We performed a systematic review and meta-analysis to evaluate the rate of dissemination and the prognosis of early and advanced stage colorectal cancer based on MSI status. Methods A systematic literature search of original studies was performed on Ovid searching MEDLINE, Embase, Cochrane Database of Systematic Reviews, American College of Physicians ACP Journal Club, Database of Abstracts of Reviews of Effects DARE, Clinical Trials databases from inception of database to June 2019. Colorectal cancer, microsatellite instability, genomic instability and DNA mismatch repair were used as key words or MeSH terms. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was followed. Data were pooled using a random-effects model with odds ratio (OR) as the effect size. Statistical analysis was performed using RevMan ver 5.3 Cochrane Collaboration. Results From 5288 studies, 136 met the inclusion criteria (n = 92,035; MSI-H 11,746 (13%)). Overall, MSI-H was associated with improved OS (OR, 0.81; 95% CI 0.73–0.90), DFS (OR, 0.73; 95% CI 0.66–0.81) and DSS (OR, 0.69; 95% CI 0.52–0.90). Importantly, MSI-H had a protective effect against dissemination with a significantly lower rate of lymph node and distant metastases. By stage, the protective effect of MSI-H in terms of OS and DFS was observed clearly in stage II and stage III. Survival in stage I CRC was excellent irrespective of MSI status. In stage IV CRC, without immunotherapy, MSI-H was not associated with any survival benefit. Conclusions MSI-H CRC was associated with an overall survival benefit with a lower rate of dissemination. Survival benefit was clearly evident in both stage II and III CRC, but MSI-H was neither a robust prognostic marker in stage I nor stage IV CRC without immunotherapy.Keywords
This publication has 157 references indexed in Scilit:
- Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian seriesAnnals of Oncology, 2013
- A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequencyThe Journal of Pathology, 2012
- Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trialBritish Journal of Cancer, 2012
- DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant TherapyJNCI Journal of the National Cancer Institute, 2011
- Microsatellite instability among individuals of Hispanic origin with colorectal cancerCancer, 2010
- BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcomeBritish Journal of Cancer, 2010
- Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapyCancer Chemotherapy and Pharmacology, 2009
- Microsatellite instability and survival in rectal cancerCancer Causes & Control, 2009
- CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancerGut, 2008
- Microsatellite instability in poorly differentiated adenocarcinomas of the colon and rectum: relationship to clinicopathological featuresJournal of Clinical Pathology, 2007